Introduction
============

Ischaemic conditioning---the induction of cyclic, non-lethal ischaemia to vascular beds around the time of the ischaemic insult---has been advocated as a means of mitigating the effects of injury including myocardial ischaemia, acute kidney injury, and stroke. It has been studied in many clinical settings, including ischaemic heart disease, stroke, cardiac surgery, transplantation, and acute kidney injury, and many potentially beneficial outcomes have been examined.

The discovery of ischaemia-reperfusion injury in myocytes in 1960 led to the development of experimental models showing that myocardial infarct size could be reduced by antecedent periods of non-lethal myocardial ischaemia.[@ref1] [@ref2] This concept was then extended by reports that inducing ischaemia in remote vascular beds (such as the kidney and small bowel) and post-insult ischaemic conditioning could similarly reduce ischaemia-reperfusion injury and myocardial infarct size.[@ref3] [@ref4] [@ref5] Although the actual mechanism of any benefit remains unclear,[@ref6] it is considered a potentially useful therapy in moderating the effects of ischaemia-reperfusion injury, especially at the time of surgery, in several organs.

The effect of ischaemic conditioning has been most widely studied in cardiovascular surgery, with some guidelines supporting its use during bypass surgery, but it has potential benefits in many other forms of ischaemic injury.[@ref7] Much of the evidence for benefit relies on effects on biomarkers and surrogate endpoints such as troponin and creatine kinase, rather than clinical endpoints. Trials that use clinical outcomes and are large enough to minimise false positive results are uncommon, leaving the clinical role of ischaemic conditioning unclear. We aimed to systematically review the evidence to assess whether ischaemic conditioning reduces important adverse clinical outcomes including all cause mortality and cardiovascular and renal events.

Methods
=======

Data sources and searches
-------------------------

We did a systematic review of the literature according to the Preferred Reporting in Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@ref8] We identified relevant trials by using a predefined search strategy (supplementary table A) of Medline (1966 to October 2015), Embase (1980 to October 2015), the Cochrane Central Register of Controlled Trials database (Central), the International Standard Registered Clinical/social sTudy Number (ISRCTN), the International Clinical Trials Registry platform (ICTRP), and the trials listed on ClinicalTrials.gov. We also manually reviewed reference lists of relevant reports. We screened titles and abstracts initially, followed by a full text review of eligible trials. We contacted lead authors of abstracts to request additional information where needed.

Study selection
---------------

Randomised controlled trials that investigated the treatment effects of ischaemic conditioning on clinical outcomes in adults or children were eligible for inclusion. All permutations of ischaemic conditioning strategies were included, including central and remote ischaemic conditioning and pre-procedural and post-procedural use of the intervention. We defined central ischaemic conditioning as the direct occlusion of a major vessel supplying the organ of interest and remote ischaemic conditioning as brief periods of ischaemia applied to a limb supplying a distant vascular bed. We defined pre-procedural and post-procedural conditioning as the application of ischaemia before or after the procedure or surgery of interest. If trials used more than one modality of ischaemic conditioning, we treated them as two separate trials with the control group divided evenly.[@ref9] Eligibility was restricted to articles using English as the language of publication.

Data extraction and quality assessment
--------------------------------------

Two independent investigators (LS and DH) extracted data on baseline characteristics of participants, characteristics of studies, and outcomes. Disagreements were resolved through discussions or referral to a third investigator (MJ).

The pre-specified main endpoint was all cause mortality, and other pre-specified outcomes included combined cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death, or as defined by study authors), myocardial infarction, stroke, new onset arrhythmia, and acute kidney injury (including need for renal replacement therapy and transplant graft function). Because of the variation in definitions used for myocardial infarction and acute kidney injury, we analysed both according to the authors' definition and according to an accepted classification system. We classified acute kidney injury according to the Acute Kidney Injury Network (AKIN) system (supplementary table B) and myocardial infarction by diagnostic criteria (single biochemical or electrocardiographic criterion "myocardial injury," diagnostic criteria not reported "unspecified myocardial ischaemia," and clinical diagnosis defined as a minimum of two diagnostic criteria including biochemical, electrocardiographic, and/or clinical syndrome "myocardial infarction") in line with the principles outlined in accepted definitions.[@ref10]

We assessed the methodological quality of each study by using the Cochrane Bias Methods Group tool.[@ref11] We summarised confidence in the evidence by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system using GRADEpro GDT (supplementary table C).[@ref12] The GRADE system assesses risk of bias, imprecision, inconsistency, indirectness of study results, and publication bias (assessing each as high, moderate, low, or very low) across the body of evidence to derive an overall summary of the quality of evidence.

Data synthesis and statistical analysis
---------------------------------------

Results are expressed as risk ratios with 95% confidence intervals obtained by a random effects model using the DerSimonian and Laird method.[@ref13] Where zero counts existed for an outcome in one arm of a trial, we added a value of 0.5 to permit meta-analysis. Where zero counts existed for an outcome in both arms of a trial, we omitted the trial from the analysis of that outcome according to Cochrane principles.[@ref11] However, we did sensitivity tests that included these trials by adding the value of 0.5 to each zero event arm,[@ref14] but we report them in this paper only if they altered the results. We used the I^2^ test to estimate heterogeneity across trials, with P\<0.1 being considered significant.

We preselected defined factors to analyse for potential heterogeneous effects on the clinical outcomes on the basis of their clinical importance for the primary outcome. These included participants' characteristics (mean age, proportion of male patients in the study, proportion of patients with diabetes in the study, paediatric or adult population), characteristics of ischaemic conditioning (ischaemic time per cycle, central or remote stimulus, upper or lower limb stimulus, pre-procedural or post-procedural ischaemic conditioning), characteristics of procedural setting (procedure for cardiac or non-cardiac condition, surgical or non-surgical setting, specific setting, use of volatile or non-volatile anaesthetic), and characteristics of study design (sample size, follow-up period, use of placebo or sham procedure as control, use of single verse multiple criteria for diagnosis of myocardial ischaemia).[@ref10] We used meta-regression to analyse continuous variables. We analysed categorical variables by using the Cochran C test, with trials weighted with the inverse variance method (a fixed effects model).

We assessed the potential for small study effects ("publication bias") affecting the primary outcome by using the Harbord and Peters methods and depicted this graphically with a funnel plot.[@ref15] [@ref16] We applied trial sequential analysis to find the required statistical information to detect a real difference between ischaemic conditioning and control groups.[@ref17] [@ref18] We used information from our meta-analysis (effect size, prevalence of outcome, heterogeneity across studies, and variance) to calculate the heterogeneity adjusted statistical information (power=0.8; α=0.05) and used this to derive the required sample size assuming that future studies would have similar characteristics to those found in our meta-analysis. We used Stata/MP 14 and Trial Sequential Analysis 0.9 Beta (Copenhagen Trial Unit, Copenhagen, Denmark) software for statistical analyses.

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results
=======

Trials and reported interventions
---------------------------------

We identified 85 reports involving 13 800 participants. Three reports included two intervention groups and one control group,[@ref19] [@ref20] [@ref21] and one report included two intervention groups and two control groups,[@ref22] resulting in the analysis of 89 trial cohorts. The 89 trial cohorts had a median of 80 participants (interquartile range 60-149) (table 1[](#tbl1){ref-type="table"}; supplementary figure A and table D). Cardiac conditions requiring surgery (43 trials) was the most common clinical setting, followed by percutaneous coronary interventions (21 trials).

###### 

Summary of included trials by setting\*

  Setting                              No of trials   No of participants   Placebo controlled trials (%)   Studies examining pre-conditioning† (%)   Remote ischaemia reperfusion stimulus‡ (%)   Use of volatile anaesthetic agents§ (%)   Median (IQR) follow-up time (months)¶   Mean (SD) age of participants (years)   Participants with diabetes (%)   Clinical outcome reported\*\* (%)         
  ------------------------------------ -------------- -------------------- ------------------------------- ----------------------------------------- -------------------------------------------- ----------------------------------------- --------------------------------------- --------------------------------------- -------------------------------- ----------------------------------- ----- ----
  Adult cardiac surgery¶¶              34             7230                 65                              91                                        71                                           67                                        1 (0.25-3)                              62 (8.8)                                27                               73                                  59    43
  Paediatric cardiac surgery\*\*\*     9              823                  89                              44                                        56                                           100                                       1 (0.5-1)                               4 (2.0)                                 NR                               100                                 11    22
  Vascular surgery†††                  7              425                  43                              100                                       86                                           67                                        1 (0.25-1)                              71 (3.7)                                16                               86                                  100   86
  Percutaneous coronary intervention   21             3 875                43                              48                                        67                                           NA                                        6 (1-12)                                63 (4.9)                                32                               62                                  57    48
  Transplantation‡‡‡                   7              487                  71                              71                                        57                                           75                                        12 (3-21)                               49 (4.9)                                7                                57                                  14    0
  Resection surgery§§§                 8              689                  0                               100                                       13                                           67                                        3 (2-3)                                 55 (4.1)                                12                               100                                 13    25
  Secondary stroke prevention¶¶¶       3              411                  67                              100                                       100                                          NA                                        6 (3-10)                                67 (17.4)                               25                               33                                  33    0

NA=not applicable; NR=not reported.

\*Full list of individual studies available in supplementary table D.

†Pre-conditioning defined as ischaemic reperfusion stimulus applied before procedure of interest.

‡Remote ischaemia reperfusion stimulus includes stimulus applied to upper limb, lower limb, or both.

§Percentage of total number of trials specifying type of anaesthetic used.

¶Intended length of follow-up.

\*\*Percentage of trials in each setting reporting mortality, cardiac, and renal outcomes.

††Mortality outcomes defined as all cause mortality.

‡‡Cardiac outcomes defined as myocardial infarction, major adverse cardiac and cerebrovascular events, and arrhythmias, as defined by study authors.

§§Renal outcomes defined as episodes of acute kidney injury, as defined by study authors.

¶¶Includes coronary artery bypass grafting (n=22), valve repair/replacement (n=8), and mixed cardiac surgery (n=7).

\*\*\*Includes correction of tetralogy of Fallot (n=2), isolated repair of ventricular septal defect (n=3), and mixed cardiac surgery (n=4).

†††Includes endoluminal (n=1), open (n=5), or both (n=1) elective abdominal aortic aneurysm repair and carotid endarterectomy procedures.

‡‡‡Includes studies in kidney (n=3), liver (n=3), and lung (n=1) transplantation.

§§§Includes hepatectomy (n=7) and lobectomy (n=1).

¶¶¶Population consisted of participants who had had a primary stroke.

Central and remote ischaemic conditioning were investigated in 32 (36%) and 57 (64%) trials respectively. Pre-conditioning and post-conditioning were investigated in 68 (76%) and 21 (24%) trials respectively. Of the 65 trials conducted in settings requiring anaesthesia, volatile anaesthetic agents were used in 34 (54%), non-volatile agents were used in 13 (20%), and the type of agent was not reported in 17 (26%). A placebo procedure was performed in the control arm in 49 (55%) trials. Intended duration of follow-up was not specified in five trials, and the remainder were designed for a median duration of one month (range 1 day to 72 months). Trials were assessed as being at high or unclear risk of bias for 27-69% of evaluated trial quality parameters (supplementary figure B).

Outcomes
--------

### Primary outcome

Ischaemic conditioning did not affect the risk of all cause mortality (68 trials; 11 619 participants; 424 events; risk ratio 0.96, 95% confidence interval 0.80 to 1.16; P=0.68), with moderate quality evidence according to GRADE assessment (fig 1[](#f1){ref-type="fig"}; supplementary table C).

![**Fig 1** Effect of ischaemic conditioning on all cause mortality. Note: does not include studies with 0 events in both arms](sukl033015.f1_default){#f1}

### Secondary outcomes

Ischaemic conditioning did not significantly reduce the risk of combined cardiovascular events (10 trials; 6114 participants; 1364 events; risk ratio 0.88, 0.73 to 1.05; P=0.16) or myocardial infarction (32 trials; 8451 participants; 714 events; risk ratio 0.84, 0.69 to 1.03; P=0.10), with moderate quality evidence according to GRADE assessment (fig 2[](#f2){ref-type="fig"}; supplementary figure C and D1; supplementary table C). When we analysed myocardial infarction according to diagnostic variability---myocardial injury, unspecified myocardial ischaemia, and myocardial infarction---the effect sizes were broadly similar (supplementary figures D2-4). Ischaemic conditioning may reduce the risk of stroke (18 trials; 5995 participants; 149 events; risk ratio 0.72, 0.52 to 1.00; P=0.048), with very low quality evidence according to GRADE assessment. The positive effect on stroke rates lost statistical significance when we included trials reporting zero events in both arms (risk ratio 0.73, 0.53 to 1.00; P=0.052) (fig 2[](#f2){ref-type="fig"}; supplementary figure E and table C)

![**Fig 2** Effect of ischaemic conditioning on secondary outcomes. Note: does not include studies with 0 events in both arms. \*Composite of major cardiovascular events as defined by study authors. †As defined by study authors. ‡Acute Kidney Injury Network (AKIN) criterion 1 derived where available from study authors' definition as per supplementary table B. §AKIN criterion 2 derived where available from study authors' definition as per supplementary table B. ¶AKIN criterion 3 derived where available from study authors' definition as per supplementary table B](sukl033015.f2_default){#f2}

Ischaemic conditioning may reduce the risk of acute kidney injury (36 trials; 8493 participants; 1443 events; risk ratio 0.83, 0.71 to 0.97; P=0.02), with low quality evidence according to GRADE assessment. When we analysed these results according to the stricter AKIN classification, the effect seemed to diminish with increasing severity of acute kidney injury (fig 2[](#f2){ref-type="fig"}; supplementary figures F1-4; supplementary table C).

Ischaemic conditioning did not reduce the risk of arrhythmias (27 trials; 6689 participants; 1380 events; risk ratio 0.90, 0.76 to 1.06; P=0.19) or transplant function: primary graft non-function (six trials; 426 participants; 22 events; risk ratio 0.69, 0.33 to 1.43; P=0.31) and delayed graft function (four trials; 266 participants; 10 events; risk ratio 0.45, 0.10 to 2.04; P=0.30) (fig 2[](#f2){ref-type="fig"}; supplementary figures G-I).

Pre-defined potential sources of heterogeneity
----------------------------------------------

For the primary outcome of all cause mortality and myocardial infarction, we found no suggestion of benefit across any of the pre-defined subgroups. There was a suggestion of increased benefit for ischaemic conditioning in non-surgical settings for stroke and acute kidney injury. Trials of proximal compared with distal ischaemic conditioning protocols were more likely to report a benefit for acute kidney injury. We found no evidence that trial quality parameters increased the likelihood of benefit being reported for ischaemic conditioning, with the exception of smaller sample size (figures 3-6[](#f3 f4 f5 f6){ref-type="fig"}; supplementary table E).

![**Fig 3** Subgroup analyses of effect of ischaemic conditioning on all cause mortality. Note: overall risk ratio for subgroup analysis derived from fixed effects model of eligible studies with ≥1 event in each arm, so may differ from main analysis method. PCI=percutaneous coronary intervention](sukl033015.f3_default){#f3}

![**Fig 4** Subgroup analyses of effect of ischaemic conditioning on myocardial infarction. Note: overall risk ratio for subgroup analysis derived from fixed effects model of eligible studies with ≥1 event in each arm, so may differ from main analysis method. PCI=percutaneous coronary intervention. \*6 trials defined myocardial infarction by single biochemical or electrocardiographic marker of ischaemia. †16 trials defined myocardial infarction by biomarker and clinical criteria. ‡14 trials did not describe their diagnostic criteria](sukl033015.f4_default){#f4}

![**Fig 5** Subgroup analyses of effect of ischaemic conditioning on stroke. Note: overall risk ratio for subgroup analysis derived from fixed effects model of eligible studies with ≥1 event in each arm, so may differ from main analysis method. PCI=percutaneous coronary intervention](sukl033015.f5_default){#f5}

![**Fig 6** Subgroup analyses of effect of ischaemic conditioning on acute kidney injury. Note: overall risk ratio for subgroup analysis derived from fixed effects model of eligible studies with ≥1 event in each arm, so may differ from main analysis method. PCI=percutaneous coronary intervention](sukl033015.f6_default){#f6}

Heterogeneity across studies
----------------------------

We found no statistical evidence of heterogeneity defined by I^2^ among studies contributing to all cause mortality, myocardial infarction, stroke, or transplant graft function. (fig 1[](#f1){ref-type="fig"}; supplementary figures D1, E, H, and I). There was evidence of heterogeneity among studies contributing to combined cardiovascular events (I^2^=54.9%; P for heterogeneity=0.02), acute kidney injury (I^2^=43.4%; P for heterogeneity=0.006), and arrhythmias (I^2^=38.7%; P for heterogeneity=0.03) (supplementary figures C, F1, and G)

Tests for small study bias
--------------------------

No statistical evidence of small study bias generally existed, although we found ambiguous results for stroke (no evidence of bias according to Harbord's modified test (P=0.68) but evidence according to Peters' test (P=0.01)) (supplementary table F; supplementary figure J).

Trial sequential analysis
-------------------------

Trial sequential analysis incorporating the characteristics of the currently reported trials, such as heterogeneity found among studies, showed that to confirm the relevant effect sizes seen in this analyses as true estimates of effect, future trials would need to include approximately a further 18 000 mortality events, 1400 myocardial infarctions, 650 strokes, and 980 episodes of acute kidney injury. Assuming that event rates were similar to those of existing trials, such an exercise would require the enrolment of an additional 490 000 participants for the total evidence to be powered to conclusively show a benefit for mortality, 17 000 to show a benefit for myocardial infarction, 25 000 to show a benefit for stroke, and 6200 to show a benefit for acute kidney injury.

Discussion
==========

This systematic review examined the effects of ischaemic conditioning on clinical outcomes in the many settings in which it has been studied. Ischaemic conditioning had no effect on mortality. Suggestions of benefit were identified for the outcomes of stroke and acute kidney injury. Doubt remains, however, about the clinical validity of these results, arising from the incongruous lack of benefit seen for the better powered combined cardiovascular events endpoint, the restriction of benefit for acute kidney injury to mild cases, and the restriction of the stroke and acute kidney injury effects to non-operative settings. In addition, few large studies have been conducted, the follow-up of participants was generally short, and the findings were only moderately precise, suggesting that insufficient evidence exists to recommend that ischaemic conditioning should be used routinely and that guideline support for the intervention may be premature.[@ref7]

Implications of findings
------------------------

These results are novel in the aggregation of data from many clinical settings, but the importance of this approach is seen in the effective ruling out of the possibility of a detectable mortality benefit from ischaemic conditioning. In addition, it highlights the remaining uncertainty about the potential benefit for the outcomes of myocardial infarction, stroke, and acute kidney injury, such that these outcomes clearly need to be the focus of future work. The ongoing 61 recruiting trials of ischaemic conditioning registered on the International Clinical Trials Registry Platform will increase the number of study participants by 4270 if completed as planned. Our trial sequential analysis shows that, assuming these ongoing trials record the same event rates as the published trials, they will recruit only two thirds of the additional participants needed to provide future meta-analyses with the power to confirm the benefit observed for acute kidney injury and an even smaller proportion of the number required to confirm a benefit for stroke or myocardial infarction.

Despite many more combined major adverse cardiovascular events being available for analysis than for the individual components (stroke, myocardial infarction), the summary effect for this outcome was smaller than the individual components. The combined cardiovascular events analysis is dominated by recent large, high quality trials, whereas the effects for the individual components of myocardial infarction and stroke were mostly generated by reports from smaller trials. In addition, definitions of these individual outcomes were variable or not available, and adjudication was not routinely performed, potentially increasing the risk of bias with the individual components compared with the combined cardiovascular events outcome.

The prevention of acute kidney injury in high risk clinical settings such as cardiovascular surgery and radiocontrast exposure is a potentially important putative benefit of ischaemic conditioning. Although an overall benefit was suggested, the observed diminution of effect size with increasing severity of AKIN defined acute kidney injury and with the higher risk surgical settings suggest that ischaemic conditioning may not be effective for the better defined severe cases of acute kidney injury that are more likely to be clinically relevant. However, the clinical benefit of small changes in serum creatinine, such as those seen with acute kidney injury of lesser severity, remains contentious and is not likely to be large.[@ref23] [@ref24]

Our ability to examine overall heterogeneity for some outcomes, including mortality, was limited by the large number of small trials with few events and wide confidence intervals. Nevertheless, it provides additional insights that may inform the design of future studies. Trials that did not use a placebo procedure in the control arm were more likely to report benefit, further suggesting that the existing literature might overstate benefits. We saw indications of greater benefit in non-surgical trials compared with surgical trials, at least for stroke and acute kidney injury. Whether this reflects a true but weak effect that is overwhelmed by the effect of the larger surgical insult or a false positive finding is not immediately clear. However, the use of volatile or non-volatile anaesthetic agents did not affect the likelihood of benefit, contrary to previous hypotheses.[@ref25] [@ref26] Generally, the characteristics of the intervention did not affect the likelihood of benefit from the intervention, with the possible exception of benefit for acute kidney injury in trials that used central compared with peripheral ischaemic conditioning.

This systematic review and meta-analysis encompasses the full range of clinical settings in which ischaemic conditioning trials have been conducted. Previous reviews have focused on specific settings, most prominently that of cardiac conditions requiring surgery. A recent review examining the effects of remote ischaemic conditioning on myocardial injury biomarkers and clinical outcomes in a meta-analysis of 44 clinical trials found lower incidence rates for myocardial infarction, major cardiac and cerebrovascular events, and all cause mortality but included markedly fewer outcome events than did our analysis,[@ref27] and it lacked the benefit of being able to include the recently published, higher quality, large scale trials.[@ref28] [@ref29] A meta-analysis of 23 trials found no effect on perioperative myocardial infarction (risk ratio 0.69, 0.34 to 1.4) or 30 day mortality (0.91, 0.43 to 1.95).[@ref30] The effects of ischaemic conditioning on acute kidney injury are also conflicting. Recent meta-analyses have found borderline effects on the risk of acute kidney injury with remote ischaemic conditioning, but the authors urged caution owing to the widely discrepant definitions used for this outcome.[@ref31] [@ref32] More broadly, the totality of the evidence summarised for the first time in this systematic review does not provide clear evidence for the benefits of this intervention.

Strengths and limitations of study
----------------------------------

This review included all randomised trials assessing ischaemic conditioning across different delivery strategies and durations in various settings in both adult and paediatric populations. Despite this variation in clinical settings, the biological premise is consistent across these studies---that periods of controlled ischaemia mitigate the severity of injury from pathological ischaemic events. Bringing this data together allows greater precision of estimates of effect but also introduces potential heterogeneity that may cloud the findings. The absence of significant statistical heterogeneity supports this approach, is an important finding itself, and is presented to guide the design of further trials. Some readers may be more interested in potential effects within certain populations and settings or with specific modalities of the intervention. The analyses include these results, although they are inherently of lower power than the overall conclusions. Conclusions drawn from the analyses must additionally be tempered by the heterogeneity of study quality and endpoint definitions, along with the awareness that the pre-specified sources of heterogeneity could not be tested in many trials. The trial sequential analyses are premised on the assumptions that the trial pool contributing to future meta-analyses would have similar characteristics to the current trial pool.

Conclusion
----------

While we await the results of future trials, this sum of evidence does not support a clinically significant effect of ischaemic conditioning on all cause mortality. Ischaemic conditioning may reduce myocardial ischaemia, stroke, and acute kidney injury, although the lack of effect on the composite outcome of major adverse cardiovascular events and attenuation of the acute kidney injury benefit with increasing outcome severity, along with the risk that existing studies have overestimated these potential benefits, raise questions about the true effects on clinical outcomes. Further high quality trials examining the effect of ischaemic conditioning on myocardial ischaemia, stroke, and acute kidney injury, particularly in non-surgical settings, are warranted. In the meantime, the current evidence does not warrant adoption into routine clinical practice.

### What is already known on this topic

1.  Ischaemic conditioning has been shown to limit tissue injury in animal models and has many potential clinical applications

2.  The role of ischaemic conditioning has been studied in many clinical settings, but the effects on patients' outcomes remain unclear

### What this study adds

1.  Ischaemic conditioning does not reduce mortality, and further research on this outcome is unlikely to be worthwhile

2.  Ischaemic conditioning may reduce myocardial ischaemia, stroke, and acute kidney injury, but further high quality trials are needed before it has any role in routine clinical practice
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